Published in Expert Opin Pharmacother on April 01, 2007
Minimal effects of ritonavir and efavirenz on the pharmacokinetics of raltegravir. Antimicrob Agents Chemother (2008) 1.16
In vitro resistance selection with doravirine (MK-1439), a novel nonnucleoside reverse transcriptase inhibitor with distinct mutation development pathways. Antimicrob Agents Chemother (2014) 0.97
Use of a physiologically-based pharmacokinetic model to simulate artemether dose adjustment for overcoming the drug-drug interaction with efavirenz. In Silico Pharmacol (2013) 0.95
Plasma concentrations, efficacy and safety of efavirenz in HIV-infected adults treated for tuberculosis in Cambodia (ANRS 1295-CIPRA KH001 CAMELIA trial). PLoS One (2014) 0.85
Impact of CYP polymorphisms, ethnicity and sex differences in metabolism on dosing strategies: the case of efavirenz. Eur J Clin Pharmacol (2014) 0.84
Artemether-Lumefantrine Combination Therapy for Treatment of Uncomplicated Malaria: The Potential for Complex Interactions with Antiretroviral Drugs in HIV-Infected Individuals. Malar Res Treat (2011) 0.81
Antiretroviral treatment in HIV-1 infected pediatric patients: focus on efavirenz. Pediatric Health Med Ther (2014) 0.79
Efavirenz-Based Regimens in Antiretroviral-Naive HIV-Infected Patients: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. PLoS One (2015) 0.78
CLEFT PALATE IN HIV-EXPOSED NEWBORNS OF MOTHERS ON HIGHLY ACTIVE ANTIRETROVIRAL THERAPY. Oral Surg (2014) 0.77
Efavirenz is predicted to accumulate in brain tissue: an in silico, in vitro and in vivo investigation. Antimicrob Agents Chemother (2016) 0.75
Towards a rational design of solid drug nanoparticles with optimised pharmacological properties. J Interdiscip Nanomed (2016) 0.75
Persistent immune activation in HIV-1 infection is associated with progression to AIDS. AIDS (2003) 5.85
CD4 cell counts of 800 cells/mm3 or greater after 7 years of highly active antiretroviral therapy are feasible in most patients starting with 350 cells/mm3 or greater. J Acquir Immune Defic Syndr (2007) 3.18
Mortality and progression to AIDS after starting highly active antiretroviral therapy. AIDS (2003) 2.78
Hypertension in sub-Saharan Africa: cross-sectional surveys in four rural and urban communities. PLoS One (2012) 2.76
GB virus C coinfection and HIV-1 disease progression: The Amsterdam Cohort Study. J Infect Dis (2005) 2.33
Implementation of an antiretroviral access program for HIV-1-infected individuals in resource-limited settings: clinical results from 4 African countries. J Acquir Immune Defic Syndr (2007) 2.05
Nevirapine and efavirenz elicit different changes in lipid profiles in antiretroviral-therapy-naive patients infected with HIV-1. PLoS Med (2004) 1.89
Incidence of and risk factors for severe hepatotoxicity associated with antiretroviral combination therapy. J Infect Dis (2002) 1.87
Integration of HIV and TB services results in improved TB treatment outcomes and earlier prioritized ART initiation in a large urban HIV clinic in Uganda. J Acquir Immune Defic Syndr (2012) 1.79
Seizing the opportunity to capitalise on the growing access to HIV treatment to expand HIV prevention. Lancet (2004) 1.66
Impact of viral hepatitis co-infection on response to antiretroviral therapy and HIV disease progression in the HIV-NAT cohort. AIDS (2004) 1.62
Are adverse events of nevirapine and efavirenz related to plasma concentrations? Antivir Ther (2005) 1.58
No treatment versus 24 or 60 weeks of antiretroviral treatment during primary HIV infection: the randomized Primo-SHM trial. PLoS Med (2012) 1.52
Risk of severe hepatotoxicity associated with antiretroviral therapy in the HIV-NAT Cohort, Thailand, 1996-2001. AIDS (2003) 1.47
HAART for the HIV-infected employees of large companies in Africa. Lancet (2006) 1.46
Access for all? Science (2004) 1.38
Criteria for drugs used in pre-exposure prophylaxis trials against HIV infection. PLoS Med (2006) 1.34
Treatment failure of nelfinavir-containing triple therapy can largely be explained by low nelfinavir plasma concentrations. Ther Drug Monit (2003) 1.28
Pharmacokinetics of nevirapine: once-daily versus twice-daily dosing in the 2NN study. HIV Clin Trials (2005) 1.16
State of affairs of tuberculosis in prison facilities: a systematic review of screening practices and recommendations for best TB control. PLoS One (2013) 1.16
Naturally HIV-1 seroconverters with lowest viral load have best prognosis, but in time lose control of viraemia. AIDS (2002) 1.13
Long-term effectiveness of combination antiretroviral therapy and prevalence of HIV drug resistance in HIV-1-infected children and adolescents in Rwanda. Pediatr Infect Dis J (2014) 1.12
Global threat from drug resistant HIV in sub-Saharan Africa. BMJ (2012) 1.11
Nelfinavir plasma concentrations are low during pregnancy. Clin Infect Dis (2004) 1.11
Nevirapine plasma concentrations and concomitant use of rifampin in patients coinfected with HIV-1 and tuberculosis. Antivir Ther (2005) 1.09
Determinants of recurrent toxicity-driven switches of highly active antiretroviral therapy. The ATHENA cohort. AIDS (2002) 1.07
Analysis of the effect of highly active antiretroviral therapy during acute HIV-1 infection on HIV-specific CD4 T cell functions. AIDS (2005) 1.06
P glycoprotein in human immunodeficiency virus type 1 infection and therapy. Antimicrob Agents Chemother (2004) 1.06
Costs of cardiovascular disease prevention care and scenarios for cost saving: a micro-costing study from rural Nigeria. J Hypertens (2015) 1.04
Stable concentrations of zidovudine, stavudine, lamivudine, abacavir, and nevirapine in serum and cerebrospinal fluid during 2 years of therapy. Antimicrob Agents Chemother (2002) 1.04
High prevalence of reduced bone mineral density in primary HIV-1-infected men. AIDS (2010) 1.02
Transient lowering of the viral set point after temporary antiretroviral therapy of primary HIV type 1 infection. AIDS Res Hum Retroviruses (2010) 1.02
Establishment of the CD4+ T-cell pool in healthy children and untreated children infected with HIV-1. Blood (2004) 1.01
A comparison of measured and estimated glomerular filtration rate in successfully treated HIV-patients with preserved renal function. Clin Nephrol (2012) 1.00
Long-term experience with combination antiretroviral therapy that contains nelfinavir for up to 7 years in a pediatric cohort. Pediatrics (2006) 0.99
Feasibility and quality of cardiovascular disease prevention within a community-based health insurance program in rural Nigeria: an operational cohort study. J Hypertens (2015) 0.98
Discontinuation of nevirapine because of hypersensitivity reactions in patients with prior treatment experience, compared with treatment-naive patients: the ATHENA cohort study. Clin Infect Dis (2008) 0.98
Significant decrease of ethinylestradiol with nevirapine, and of etonogestrel with efavirenz in HIV-positive women. J Acquir Immune Defic Syndr (2014) 0.97
Persistent decline in estimated but not measured glomerular filtration rate on tenofovir may reflect tubular rather than glomerular toxicity. AIDS (2011) 0.96
Efavirenz, in contrast to nevirapine, is associated with unfavorable progesterone and antiretroviral levels when coadministered with combined oral contraceptives. J Acquir Immune Defic Syndr (2013) 0.95
HIV infection is independently associated with frailty in middle-aged HIV type 1-infected individuals compared with similar but uninfected controls. AIDS (2016) 0.95
Use of composite end points to measure clinical events. JAMA (2003) 0.95
Effects of active treatment discontinuation in patients with a CD4+ T-cell nadir greater than 350 cells/mm3: 48-week Treatment Interruption in Early Starters Netherlands Study (TRIESTAN). J Acquir Immune Defic Syndr (2007) 0.93
Interindividual variability of once-daily ritonavir boosted saquinavir pharmacokinetics in Thai and UK patients. J Antimicrob Chemother (2005) 0.93
Discordant responses during antiretroviral therapy: role of immune activation and T cell redistribution rather than true CD4 T cell loss. AIDS (2002) 0.92
Reconstitution of EBV latent but not lytic antigen-specific CD4+ and CD8+ T cells after HIV treatment with highly active antiretroviral therapy. J Immunol (2005) 0.90
Once-daily highly active antiretroviral therapy for HIV-infected children: safety and efficacy of an efavirenz-containing regimen. Pediatrics (2007) 0.90
Semen quality and drug concentrations in seminal plasma of patients using a didanosine or didanosine plus tenofovir containing antiretroviral regimen. Ther Drug Monit (2007) 0.88
Quality of life in patients treated with first-line antiretroviral therapy containing nevirapine and/or efavirenz. Antivir Ther (2004) 0.88
Safety, tolerability, and immunogenicity after 1 and 2 doses of zoster vaccine in healthy adults ≥60 years of age. Vaccine (2011) 0.88
Long-term highly active antiretroviral therapy in chronic HIV-1 infection: evidence for reconstitution of antiviral immunity. Antivir Ther (2006) 0.88
Dose-escalating study of the safety and pharmacokinetics of nelfinavir in HIV-exposed neonates. J Acquir Immune Defic Syndr (2002) 0.88
Functional restoration of human immunodeficiency virus and Epstein-Barr virus-specific CD8(+) T cells during highly active antiretroviral therapy is associated with an increase in CD4(+) T cells. Eur J Immunol (2002) 0.88
Low versus high CD4 cell count as starting point for introduction of antiretroviral treatment in resource-poor settings: a scenario-based analysis. Antivir Ther (2003) 0.87
Advanced liver fibrosis by transient elastography, fibrosis 4, and alanine aminotransferase/platelet ratio index among Asian hepatitis C with and without human immunodeficiency virus infection: role of vitamin D levels. J Gastroenterol Hepatol (2014) 0.87
Improved long-term suppression of HIV-1 replication with a triple-class multidrug regimen compared with standard of care antiretroviral therapy. AIDS (2002) 0.87
Limited penetration of lopinavir into seminal plasma of HIV-1-infected men. AIDS (2002) 0.87
Is the male genital tract really a sanctuary site for HIV? Arguments that it is not. AIDS (2004) 0.86
Effect of mycophenolate mofetil on the pharmacokinetics of antiretroviral drugs and on intracellular nucleoside triphosphate pools. Clin Pharmacokinet (2004) 0.85
Peptide inhibitors of virus-cell fusion: enfuvirtide as a case study in clinical discovery and development. Lancet Infect Dis (2004) 0.85
Unrecognised tuberculosis at antiretroviral therapy initiation is associated with lower CD4+ T cell recovery. Trop Med Int Health (2012) 0.85
Low bone mineral density, regardless of HIV status, in men who have sex with men. J Infect Dis (2012) 0.85
No virological failure in semen during properly suppressive antiretroviral therapy despite subtherapeutic local drug concentrations. HIV Clin Trials (2007) 0.84
Pharmacokinetics of indinavir/ritonavir (800/100 mg) in combination with efavirenz (600 mg) in HIV-1-infected subjects. J Acquir Immune Defic Syndr (2003) 0.84
Three-year durability of dual-nucleoside versus triple-nucleoside therapy in a Thai population with HIV infection. J Acquir Immune Defic Syndr (2004) 0.83
Intravenous immunoglobulin (IVIG) treatment for modulation of immune activation in human immunodeficiency virus type 1 infected therapy-naive individuals. AIDS Res Hum Retroviruses (2007) 0.83
Changes in body composition and mitochondrial nucleic acid content in patients switched from failed nucleoside analogue therapy to ritonavir-boosted indinavir and efavirenz. J Infect Dis (2006) 0.83
TMC125 exerts similar initial antiviral potency as a five-drug, triple class antiretroviral regimen. AIDS (2003) 0.82
Highly active antiretroviral therapy with or without mycophenolate mofetil in treatment-naive HIV-1 patients. AIDS (2004) 0.82
The pharmacokinetics of nelfinavir in HIV-1-infected children. Ther Drug Monit (2002) 0.82
Relationship between hyperbilirubinaemia and UDP-glucuronosyltransferase 1A1 (UGT1A1) polymorphism in adult HIV-infected Thai patients treated with indinavir. Pharmacogenet Genomics (2006) 0.82
Cytomegalovirus rather than HIV triggers the outgrowth of effector CD8+CD45RA+CD27- T cells in HIV-1-infected children. AIDS (2005) 0.82
White matter structure alterations in HIV-1-infected men with sustained suppression of viraemia on treatment. AIDS (2016) 0.82
Mortality risk factors among HIV-exposed infants in rural and urban Cameroon. Trop Med Int Health (2014) 0.81
The impact of hormonal contraception and pregnancy on sexually transmitted infections and on cervicovaginal microbiota in african sex workers. Sex Transm Dis (2015) 0.81
Dynamics of the pool of infected resting CD4 HLA-DR- T lymphocytes in patients who started a triple class five-drug antiretroviral regimen during primary HIV-1 infection. Antivir Ther (2003) 0.81
Dyslipidemia in an Asian population after treatment for two years with protease inhibitor-containing regimens. J Int Assoc Physicians AIDS Care (Chic) (2007) 0.81
Viral dynamics after starting first-line HAART in HIV-1-infected children. AIDS (2006) 0.81
Plasma HIV-1 RNA decline within the first two weeks of treatment is comparable for nevirapine, efavirenz, or both drugs combined and is not predictive of long-term virologic efficacy: A 2NN substudy. J Acquir Immune Defic Syndr (2005) 0.80
Both R5 and X4 human immunodeficiency virus type 1 variants persist during prolonged therapy with five antiretroviral drugs. J Virol (2002) 0.80
Population pharmacokinetics of itraconazole in Thai HIV-1-infected persons. Ther Drug Monit (2003) 0.80
The use of pharmacokinetically guided indinavir dose reductions in the management of indinavir-associated renal toxicity. J Antimicrob Chemother (2006) 0.80
Antiviral activity of HIV type 1 protease inhibitors nelfinavir and indinavir in vivo is not influenced by P-glycoprotein activity on CD4+ T cells. AIDS Res Hum Retroviruses (2007) 0.78
White matter hyperintensities in relation to cognition in HIV-infected men with sustained suppressed viral load on combination antiretroviral therapy. AIDS (2016) 0.77
A phase I/IIa study with succinylated human serum albumin (Suc-HSA), a candidate HIV-1 fusion inhibitor. Antivir Ther (2007) 0.77
Markedly diminished lipolysis and partial restoration of glucose metabolism, without changes in fat distribution after extended discontinuation of protease inhibitors in severe lipodystrophic human immunodeficient virus-1-infected patients. J Clin Endocrinol Metab (2004) 0.77
Stavudine but not didanosine as part of HAART contributes to peripheral lipoatrophy: a substudy from the Antiretroviral Regimen Evaluation Study (ARES). HIV Clin Trials (2007) 0.77
Evaluation of nevirapine and/or hydroxyurea with nucleoside reverse transcriptase inhibitors in treatment-naive HIV-1-infected subjects. AIDS (2004) 0.77
Difference in Aortic Stiffness Between Treated Middle-Aged HIV Type 1-Infected and Uninfected Individuals Largely Explained by Traditional Cardiovascular Risk Factors, With an Additional Contribution of Prior Advanced Immunodeficiency. J Acquir Immune Defic Syndr (2016) 0.77
Viral decay dynamics in HIV-infected patients receiving ritonavir-boosted saquinavir and efavirenz with or without enfuvirtide: a randomized, controlled trial (HIV-NAT 012). J Infect Dis (2006) 0.76